Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.15
+0.39001.88%
Post-market: 21.150.00000.00%16:20 EDT
Volume:2.33M
Turnover:48.90M
Market Cap:1.88B
PE:-5.19
High:21.71
Open:21.09
Low:20.15
Close:20.76
Loading ...

BUZZ-Guggenheim raises PT on Travere Therapeutics

Reuters
·
14 Jan

Wells Fargo Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
14 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX), Treace Medical Concepts (TMCI) and X4 Pharmaceuticals (XFOR)

TIPRANKS
·
14 Jan

BRIEF-Travere Therapeutics Provides Corporate Update And 2025 Outlook

Reuters
·
13 Jan

Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook

Dow Jones
·
13 Jan

Travere Therapeutics Inc: Expects Fiscal Year 2024 Net Product Sales to Be Approximately $227 Mln

THOMSON REUTERS
·
13 Jan

Travere Therapeutics Provides Corporate Update and 2025 Outlook

THOMSON REUTERS
·
13 Jan

Travere Therapeutics- Snda for Modification of Liver Monitoring for Filspari in Igan Accepted for FDA Review ; Pdufa Target Action Date of Aug 28

THOMSON REUTERS
·
13 Jan

Travere Therapeutics Inc: on Track to Provide Regulatory Update on Sparsentan in Fsgs by Its Q4 2024 Earnings Call

THOMSON REUTERS
·
13 Jan

Cantor Fitzgerald Initiates Travere Therapeutics at Overweight

MT Newswires Live
·
10 Jan

High Growth Tech Stocks in the United States to Watch

Simply Wall St.
·
02 Jan

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain

Simply Wall St.
·
26 Dec 2024

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
26 Nov 2024

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

seekingalpha
·
26 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

JPMorgan’s ‘Analyst Focus List’ – growth, income, value, short ideas

seekingalpha
·
20 Nov 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Blockhead
·
19 Nov 2024

MHRA approves Travere’s sparsentan to treat adults with primary IgAN

TIPRANKS
·
19 Nov 2024

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.
·
16 Nov 2024

Travere Therapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
14 Nov 2024